|Calculated MW||58827 Da|
|Other Names||Keratin, type I cytoskeletal 10, Cytokeratin-10, CK-10, Keratin-10, K10, KRT10, KPP|
|Target/Specificity||A synthetic peptide corresponding to residues in the C-term of human Cytokeratin 10 was used as immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Cytokeratin-10 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Plays a role in the establishment of the epidermal barrier on plantar skin.|
|Cellular Location||Secreted, extracellular space. Note=Localized on the surface of desquamated nasal epithelial cells.|
|Tissue Location||Seen in all suprabasal cell layers including stratum corneum|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Cytokeratin 10 (CK10) is a heterotetramer of two type I and two type II keratins. CK10 is typically associated with cytokeratin 1 (CK1). CK10 is expressed in all suprabasal cell layers, and it is part of the acidic/high molecular weight keratin subfamily. Defects in CK10 cause Epidermolytic hyperkeratosis (EHK), a hereditary skin hereditary skin disorder characterized by blistering and a marked thickening of the stratum corneum (1). CK10 has also been linked to cause annular epidermolytic ichthyosis (AEI), also known as cyclic ichthyosis with epidermolytic hyperkeratosis. CK10, along with CK14, 15, 16, and 20, can be used to determine if a neoplasm originated from an epithelial or non-epithelial origin, such as the determination of metastatic malignant tumors of epithelial origin (2).
1. McGowan, K, et al; Journal of Investigative Dermatology 126:1013
2. Lin, Y, et al; Modern Pathology 17:1129
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.